From ONYX-015 to armed vaccinia viruses: The education and evolution of oncolytic virus development

Current Cancer Drug Targets

Volumn 7, Issue 2, 2007, Pages 133-139

  Crompton, Anne Moon ^a,c   Kirn, David H ^a,b,c  

^a Jennerex Biotherapeutics   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c Spear Tower ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVEXIN; ANTINEOPLASTIC AGENT; CISPLATIN; CYTOSINE DEAMINASE; DOXORUBICIN; ERLOTINIB; FLUCYTOSINE; FLUOROURACIL; GANCICLOVIR; GEFITINIB; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; H 101; JX 594; JX 963; MONOCLONAL ANTIBODY; ONCOLYTIC ADENOVIRUS; ONCOLYTIC NEWCASTLE VIRUS; ONCOLYTIC VACCINIA VIRUS; ONCOLYTIC VIRUS; ONYX 015; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; TEMOZOLOMIDE; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; CANCER REGRESSION; CLINICAL TRIAL; COLORECTAL CARCINOMA; COMBINATION CHEMOTHERAPY; CYTOTOXICITY; DEHYDRATION; DIARRHEA; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG SYNTHESIS; DYSPNEA; FEVER; FLU LIKE SYNDROME; HEAD AND NECK CANCER; HEART OUTPUT; HERPES SIMPLEX VIRUS; HUMAN; INJECTION SITE PAIN; INJECTION SITE REACTION; LYMPHOCYTOPENIA; MELANOMA; METASTASIS; MONOTHERAPY; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; REOVIRUS; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TUMOR CELL; VACCINIA VIRUS; VIRUS REPLICATION; VOMITING;

ADENOVIRIDAE; ANIMALS; COMBINED MODALITY THERAPY; HUMANS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; TREATMENT OUTCOME; VACCINIA VIRUS; VIRUS REPLICATION;

EID: 33847370331     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800907780058862     Document Type: Review

References (51)

1. Bischoff, J. R.; Kirn, D. H.; Williams, A.; Heise, C.; Horn, S.; Muna, M.; Ng, L.; Nye, J. A.; Sampson-Johannes, A.; Fattaey, A.; McCormick, F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996, 274, 373-376.
2. Heise, C.; Sampson, J. A.; Williams, A.; McCormick, F.; Von, H. D.; Kirn, D. H. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents [see comments]. Nat. Med. 1997, 3, 639-645.
3. Ganly, I.; Kirn, D.; Eckhardt, S.; Rodriguez, G.; Souter, D.; Von Hoff, D.; Kaye, S. A phase I study of ONYX-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin. Cancer Res. 2000, 6, 798-806.
4. Nemunaitis, J.; Ganly, I.; Khuri, F.; Arsenau, J.; Kuhn, J.; McCarty, T.; Landers, S.; Maples, P.; Romel, L.; Randlev, B.; Reid, T.; Kaye, S.; Kirn, D. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res. 2000, 60, 6359-6366.
5. Morley, S.; MacDonald, G.; Kirn, D.; Kaye, S.; Brown, R.; Soutar, D. The dl1520 virus is found preferentially in tumor tissue after direct intratumoral injection in oral carcinoma. Clin. Cancer Res. 2004, 10, 4357-4362.
6. Khuri, F.; Nemunaitis, J.; Ganly, I.; Gore, M.; MacDougal, M.; Tannock, I.; Kaye, S.; Hong, W.; Kirn, D. A controlled trial of ONYX-015, an E1B gene-deleted adenovirus, in combination with chemotherapy in patients with recurrent head and neck cancer. Nat. Med. 2000, 6, 879-885.
7. Kirn, D. Clinical research results with dl1520 (ONYX-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Ther. 2001, 8, 89-98.
8. McCart, J. A.; Puhlmann, M.; Lee, J.; Hu, Y.; Libutti, S. K.; Alexander, H. R.; Bartlett, D. L. Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression. Gene Ther. 2000, 7, 1217-1223.
9. Aghi, M.; Rabkin, S.; Martuza, R. L. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. J. Natl. Cancer Inst. 2006, 98, 38-50.
10. Chahlavi, A.; Todo, T.; Martuza, R. L.; Rabkin, S. D. Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia 1999, 1, 162-169.
11. Eisenberg, D. P.; Adusumilli, P. S.; Hendershott, K. J.; Yu, Z.; Mullerad, M.; Chan, M. K.; Chou, T. C.; Fong, Y. 5-Fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer. J. Gastrointest. Surg. 2005, 9, 1068-1077; discussion 1077-1079.
12. Freytag, S. O.; Stricker, H.; Pegg, J.; Paielli, D.; Pradhan, D. G.; Peabody, J.; DePeralta-Venturina, M.; Xia, X.; Brown, S.; Lu, M.; Kim, J. H. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res. 2003, 63, 7497-7506.
13. Vasey, P.; Seiden, M.; O'Neill, V.; Campo, S.; Johnston, S.; Davis, J.; Kirn, D.; Kaye, S.; Shulman, L. Phase I trial of intraperitoneal ONYX-015 adenovirus in patients with recurrent ovarian cancer. J. Clin. Oncol. 2002, 20(6), 1562-1569.
14. Reid, T.; Galanis, E.; Abbruzzese, J.; Sze, D.; Wein, L. M.; Andrews, J.; Randlev, B.; Heise, C.; Uprichard, M.; Hatfield, M.; Rome, L.; Rubin, J.; Kirn, D. Hepatic arterial infusion of a eplication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res. 2002, 62, 6070-6079.
15. Reid, T.; Warren, R.; Kirn, D. Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther. 2002, 9, 979-986.
16. Nemunaitis, J.; Cunningham, C.; Buchanan, A.; Blackburn, A.; Edelman, G.; Maples, P.; Netto, G.; Tong, A.; Randlev, B.; Olson, S.; Kirn, D. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther. 2001, 8, 746-759.
17. Hamid, O.; Varteresian, M.; Wadler, S.; Benson, A.; Uprichard, M.; Galanis, E.; Omer, C.; Hackman, R.; Shields, A. Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer. J. Clin. Oncol. 2003, 21, 1498-1504.
18. Wu, J. T.; Kirn, D. H.; Wein, L. M. Analysis of a three-way race between tumor growth, a replication-competent virus and an immune response. Bull. Math. Biol. 2004, 66, 605-625.
19. Wein, L. M.; Wu, J. T.; Kirn, D. H. Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery. Cancer Res. 2003, 63, 1317-1324.
20. Small, E. J.; Carducci, M. A.; Burke, J. M.; Rodriguez, R.; Fong, L.; van Ummersen, L.; Yu, D. C.; Aimi, J.; Ando, D.; Working, P.; Kirn, D.; Wilding, G. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol. Ther. 2006, 14, 107-117.
21. Mastrangelo, M. J.; Maguire, H. C., Jr.; Eisenlohr, L. C.; Laughlin, C. E.; Monken, C. E.; McCue, P. A.; Kovatich, A. J.; Lattime, E. C. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther. 1999, 6, 409-422.
22. Markert, J. M.; Medlock, M. D.; Rabkin, S. D.; Gillespie, G. Y.; Todo, T.; Hunter, W. D.; Palmer, C. A.; Feigenbaum, F.; Tornatore, C.; Tufaro, F.; Martuza, R. L. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 2000, 7, 867-874.
23. Pecora, A. L.; Rizvi, N.; Cohen, G. I.; Meropol, N. J.; Sterman, D.; Marshall, J. L.; Goldberg, S.; Gross, P.; O'Neil, J. D.; Groene, W. S.; Roberts, M. S.; Rabin, H.; Bamat, M. K.; Lorence, R. M. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J. Clin. Oncol. 2002, 20, 2251-2266.
24. Thorne, S. H.; Hermiston, T.; Kirn, D. Oncolytic Virotherapy: Approaches to tumor targeting and enhancing antitumor effects. Semin. Oncol. 2005, 32, 537-548.
25. Gomella, L. G.; Mastrangelo, M. J.; McCue, P. A.; Maguire, H. C. J.; Mulholland, S. G.; Lattime, E. C. Phase I study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer. J. Urol. 2001, 166, 1291-1295.
26. Hunter-Craig, I.; Newton, K.; Westbury, G.; Lacey, B. Use of vaccinia virus in the treatment of metastatic malignant melanoma. Br. Med. J. 1970, 2, 512-515.
27. Roenigk, H.; Deodhar, S.; Jacques, R.; Burdick, K. Immunotherapy of malignant melanoma with vaccinia virus. Arch. Dermatol. 1974, 109, 668-673.
28. Arakawa, S. J.; Hamami, G.; Umezu, K.; Kamidono, S.; Ishigami, J.; Arakawa, S. Clinical trial of attenuated vaccinia virus as strain in the treatment of advanced adenocarcinoma. Report on two cases. J. Cancer Res. Clin. 1987, 113, 95-98.
29. Burdick, K.; Hawk, W. Vitiligo in a case of vaccinia virus-treated melanoma. Cancer 1964, 17, 708-712.
30. Hansen, R. M.; Libnoch, J. A. Remission of chronic lymphocytic leukemia after smallpox vaccination. Arch. Intern. Med. 1978, 138, 1137-1138.
31. Kawa, A.; Arakawa, S. The effect of attenuated vaccinia virus AS strain on multiple myeloma; a case report. Jpn. J. Exp. Med. 1987, 57, 79-81.
32. Fisher, K. D.; Stallwood, Y.; Green, N. K.; Ulbrich, K.; Mautner, V.; Seymour, L. W. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther. 2001, 8, 341-348.
33. Lam, J. T.; Bauerschmitz, G. J.; Kanerva, A.; Barker, S. D.; Straughn, J. M.; Wang, M.; Barnes, M. N.; Blackwell, J. L.; Siegal, G. P.; Alvarez, R. D.; Curiel, D. T.; Hemminki, A. Replication of an integrin targeted conditionally replicating adenovirus on primary ovarian cancer spheroids. Cancer Gene Ther. 2003, 10, 377-387.
34. Gnant, M. F.; Noll, L. A.; Irvine, K. R.; Puhlmann, M.; Terrill, R. E.; Alexander, H. R., Jr.; Bartlett, D. L. Tumor-specific gene delivery using recombinant vaccinia virus in a rabbit model of liver metastases. J. Natl. Cancer Inst. 1999, 91, 1744-1750.
35. McCart, J. A.; Ward, J. M.; Lee, J.; Hu, Y.; Alexander, H. R.; Libutti, S. K.; Moss, B.; Bartlett, D. L. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res. 2001, 61, 8751-8757.
36. Kirn, D.; Martuza, R. L.; Zwiebel, J. Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat. Med. 2001, 7, 781-787.
37. Nemunaitis, J.; Khuri, F.; Ganly, I.; Arseneau, J.; Posner, M.; Vokes, E.; Kuhn, J.; McCarty, T.; Landers, S.; Blackburn, A.; Romel, L.; Randlev, B.; Kaye, S.; Kirn, D. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J. Clin. Oncol. 2001, 19, 289-298.
38. Bischoff, J. R.; Kirn, D. H.; Williams, A.; Heise, C.; Horn, S.; Muna, M.; Ng, L.; Nye, J. A.; Sampson-Johannes, A.; Fattaey, A.; McCormick, F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells [see comments]. Science 1996, 274, 373-376.
39. Rogulski, K.; Freytag, S.; Zhang, K.; Gilbert, J.; Paielli, D.; Kim, J.; Heise, C.; Kirn, D. H. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res. 2000, 60, 1193-1196.
40. Rothmann, T.; Hengstermann, A.; Whitaker, N. J.; Scheffner, M.; zur Hausen, H. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J. Virol. 1998, 72, 9470-9478.
41. Ries, S. J.; Brandts, C. H.; Chung, A. S.; Biederer, C. H.; Hann, B. C.; Lipner, E. M.; McCormick, F.; Korn, M. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat. Med. 2000, 6, 1128-1133.
42. Harada, J.; Berk, A. p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication. J. Virol. 1999, 73, 5333-5344.
43. O'Shea, C. C.; Johnson, L.; Bagus, B.; Choi, S.; Nicholas, C.; Shen, A.; Boyle, L.; Pandey, K.; Soria, C.; Kunich, J.; Shen, Y.; Habets, G.; Ginzinger, D.; McCormick, F. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 2004, 6, 611-623.
44. O'Shea, C. C.; Soria, C.; Bagus, B.; McCormick, F. Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. Cancer Cell 2005, 8, 61-74.
45. McCart, A.; Ward, J.; Lee, J.; Hu, Y.; Alexander, H.; Libutti, S.; Moss, B.; Bartlett, D. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res. 2001, 61, 8751-8757.
46. Puhlmann, M.; Brown, C. K.; Gnant, M.; Huang, J.; Libutti, S. K.; Alexander, H. R.; Bartlett, D. L. Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Ther. 2000, 7, 66-73.
47. Strong, J.; Coffey, M.; Tang, D.; Sabinin, P.; Lee, P. The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J. 1998, 17, 3351-3362.
48. Stojdl, D. F.; Lichty, B.; Knowles, S.; Marius, R.; Atkins, H.; Sonenberg, N.; Bell, J. C. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med. 2000, 6, 821-825.
49. Reichard, K. W.; Lorence, R. M.; Cascino, C. J.; Peeples, M. E.; Walter, R. J.; Fernando, M. B.; Reyes, H. M.; Greager, J. A. Newcastle disease virus selectively kills human tumor cells. J. Surg. Res. 1992, 52, 448-453.
50. Bergmann, M.; Romirer, I.; Sachet, M.; Fleischhacker, R.; Garcia-Sastre, A.; Palese, P.; Wolff, K.; Pehamberger, H.; Jakesz, R.; Muster, T. A genetically engineered influenza A virus with Ras-dependent oncolytic properties. Cancer Res. 2001, 61, 8188-8193.
51. Stojdl, D. F.; Lichty, B. D.; tenOever, B. R.; Paterson, J. M.; Power, A. T.; Knowles, S.; Marius, R.; Reynard, J.; Poliquin, L.; Atkins, H.; Brown, E. G.; Durbin, R. K.; Durbin, J. E.; Hiscott, J.; Bell, J. C. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003, 4, 263-275.